Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).

Temozolomide (CCRG 81045: M&B 39831: NSC 362856) is an analogue of mitozolomide displaying similar broad spectrum activity in mouse tumours, but showing considerably less myelosuppression in the toxicology screen. Temozolomide was initially studied intravenously at doses between 50-200 mg m-2 an...

Descripción completa

Detalles Bibliográficos
Autores principales: Newlands, E. S., Blackledge, G. R., Slack, J. A., Rustin, G. J., Smith, D. B., Stuart, N. S., Quarterman, C. P., Hoffman, R., Stevens, M. F., Brampton, M. H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1992
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977719/
https://www.ncbi.nlm.nih.gov/pubmed/1739631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977719/
https://www.ncbi.nlm.nih.gov/pubmed/1739631

Ejemplares similares